Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients
- 18 July 2018
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 38 (11) , 1906-1910
Abstract
Background & Aims: AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with interferon‐free regimens. However, it remains unclear how to respond to a detectable or even quantifiable HCV RNA result. The aim of this study was to analyse the frequency and predictive value of detectable and quantifiable HCV RNA results at the EOT in patients with HCV genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real‐world cohort.Methods: A retrospective analysis of the DHC‐R (Deutsches Hepatitis C‐Register, German Hepatitis C‐Registry) cohort was performed including all patients who were treated with LDV/SOF ± RBV and in whom HCV RNA testing was done with either the Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) or the Abbott RealTime HCV assay (ART).Results: The frequency of detectable HCV RNA at the EOT was 7% in this real‐world study involving 471 patients. Furthermore, 3% of the patients (n = 14/471) even had quantifiable viral load at the EOT. Detectable and quantifiable results were more frequent if the ART was used for testing. However, SVR was achieved by 32/33 patients (97%) with detectable and even by all 14 patients (100%) with quantifiable HCV RNA results at the EOT.Conclusion: Detectable and even quantifiable HCV RNA results are quite frequent if highly sensitive HCV RNA assays are used. However, treatment prolongation is not indicated, as SVR rates remain high in these patients.Keywords
Funding Information
- Gilead Sciences
- Merck Sharp and Dohme United Kingdom
- Janssen Pharmaceutica
- F. Hoffmann-La Roche
- Deutsches Zentrum für Infektionsforschung
- Bristol-Myers Squibb
- AbbVie Deutschland
This publication has 10 references indexed in Scilit:
- EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology, 2018
- Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case SeriesGastroenterology, 2017
- Diagnostics in hepatitis C: The end of response-guided therapy?Journal of Hepatology, 2016
- Direct-Acting Antiviral–Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis CThe Journal of Infectious Diseases, 2016
- Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimensJournal of Hepatology, 2016
- Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapyEuropean Journal of Immunology, 2016
- Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral TherapyClinical Infectious Diseases, 2015
- Innate and adaptive immune responses in HCV infectionsJournal of Hepatology, 2014
- Restoration of HCV-specific CD8+ T cell function by interferon-free therapyJournal of Hepatology, 2014
- Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infectionJournal of Hepatology, 2014